“Submission of Letter of Offer pertaining to buyback of up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) fully paid-up equity shares having a face value of ₹1/- (Rupees One only) each (“Equity Shares”) of Aurobindo Pharma Limited (“Company”) at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share payable in cash for an aggregate amount not exceeding ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only) on a proportionate basis through tender offer route (“Buyback”), pursuant to the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (“Buyback Regulations”),” Aurobindo Pharma said in an exchange filing on Tuesday, April 21.
